Zhou Ling, Chen Zijun, Jiang Riyue, Hu Yimin, Zhu Bin, Yang Chun, Yang Ling, Liu Cunming
Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, 210029 Nanjing, Jiangsu, China.
Department of Cardiology, The Third Affiliated Hospital of Soochow University, 213003 Changzhou, Jiangsu, China.
Rev Cardiovasc Med. 2022 Sep 5;23(9):298. doi: 10.31083/j.rcm2309298. eCollection 2022 Sep.
The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global public health emergency. As the number of confirmed cases increases, cardiovascular complications, such as myocardial injury and cardiac dysfunction, are evidenced. Takotsubo syndrome (TTS), which is common in the intensive care unit, is diagnosed among COVID-19 patients. There have been 68 more cases reports with over 119 patients since a COVID-19 patient with TTS was first reported on April 14, 2020. Angiotensin-converting enzyme 2 (ACE2), which is widely expressed in the lungs and heart, is the virus receptor. Nevertheless, randomized studies on COVID-19 related TTS are lacking, and the pathogenesis and pathophysiology are still unclear. Therefore, this review provides an overview of the potential pathogenesis, pathophysiology, clinical manifestations, diagnosis, and treatment strategy for TTS in the COVID-19 era based on current practices.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019年新型冠状病毒病（COVID-19）大流行已成为全球突发公共卫生事件。随着确诊病例数量的增加，心血管并发症，如心肌损伤和心脏功能障碍，已得到证实。在重症监护病房中常见的应激性心肌病（TTS）在COVID-19患者中被诊断出来。自2020年4月14日首次报告一名患有TTS的COVID-19患者以来，已有68例以上病例报告，涉及119名以上患者。血管紧张素转换酶2（ACE2）在肺和心脏中广泛表达，是该病毒的受体。然而，缺乏关于COVID-19相关TTS的随机研究，其发病机制和病理生理学仍不清楚。因此，本综述基于当前实践，概述了COVID-19时代TTS的潜在发病机制、病理生理学、临床表现、诊断和治疗策略。
